Cargando...
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression o...
Guardado en:
| Publicado en: | Therap Adv Gastroenterol |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4984328/ https://ncbi.nlm.nih.gov/pubmed/27582886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16650155 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|